-+ 0.00%
-+ 0.00%
-+ 0.00%

BridgeBio Pharma's Acoramidis Receives Marketing Authorization From Brazil's Health Regulatory Agency To Treat Transthyretin Amyloidosis

Benzinga·05/06/2026 11:42:30
Listen to the news

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization for acoramidis, under the brand name BEYONTTRA, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered near-complete (≥90%) transthyretin (TTR) stabilizer.